CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference in New York, NY.
Company management will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" on Thursday, October 9, 2025, at 8:00 AM ET. The company will also be available for one-on-one meetings with institutional investors during the conference.
Details
News Market Reaction – CRVO
On Oct 2, the day this news came out, CRVO closed 1.74% above the previous close.
Data tracked by StockTitan Argus for the Oct 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025.
Panel Details
Title: “Small Firms Tackling Blockbuster Indications”
Date: Thursday, October 9, 2025
Time: 8:00 AM ET
To request a meeting or for more details about the Conference, please reach out to your institutional representative at Roth.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company’s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.